Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

0.6001
-0.0419-6.53%
Volume:2.02M
Turnover:1.24M
Market Cap:111.68M
PE:-1.04
High:0.6430
Open:0.6430
Low:0.5949
Close:0.6420
Loading ...

Nektar Therapeutics Partners With TrialNet to Test Rezpegaldesleukin in Type 1 Diabetes

MT Newswires Live
·
24 Feb

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients With New Onset Type 1 Diabetes Mellitus

THOMSON REUTERS
·
24 Feb

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

PR Newswire
·
24 Feb

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

PR Newswire
·
24 Feb

B.Riley Financial Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)

TIPRANKS
·
17 Feb

Lacklustre Performance Is Driving Nektar Therapeutics' (NASDAQ:NKTR) 34% Price Drop

Simply Wall St.
·
10 Feb

Nektar Says FDA Grants Fast-Track Designation to Atopic Dermatitis Treatment

MT Newswires Live
·
10 Feb

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS
·
10 Feb

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

PR Newswire
·
10 Feb

Nektar Therapeutics' (NASDAQ:NKTR) latest 18% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.
·
09 Feb

Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround

Zacks
·
07 Feb

Nektar Names Kotzin Interim Chief Medical Officer

Dow Jones
·
05 Feb

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

Zacks
·
03 Feb

Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks
·
31 Jan

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Zacks
·
31 Jan

MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

Zacks
·
27 Jan

Analysts Are Bullish on These Healthcare Stocks: Monopar Therapeutics Inc (MNPR), Nektar Therapeutics (NKTR)

TIPRANKS
·
22 Jan

Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.

Dow Jones
·
13 Jan

Nektar Therapeutics: Promising Drug Pipeline and Strategic Expansion Drive Buy Rating

TIPRANKS
·
13 Jan

Buy Rating for Nektar Therapeutics: Promising Clinical Trial Strategy and Efficacy of Rezpeg

TIPRANKS
·
11 Jan